Optimi Health Provides Corporate Update
Rhea-AI Summary
Optimi Health (OTCQX: OPTHF), a GMP-certified MDMA and psilocybin manufacturer, has announced two significant updates. First, the company has engaged MZ Investor Relations for strategic capital markets support at US$9,000-13,500 monthly, granting them 1.9 million stock options with varying exercise prices and vesting schedules.
On the manufacturing front, Optimi has achieved a milestone by completing production of over 3,000 GMP doses of 5mg natural psilocybin extract capsules. These will be used to treat Treatment-Resistant Depression patients in Australia and supply upcoming Phase 2 clinical trials globally. The company offers GMP-certified MDMA capsules (40mg and 60mg), psilocybin capsules, and APIs to licensed distributors and pharmaceutical companies.
Positive
- Successfully manufactured over 3,000 GMP doses of psilocybin capsules for clinical use
- Expanded market reach through engagement with MZ Investor Relations for strategic capital markets support
- Products available for Treatment-Resistant Depression treatment in Australia under Authorized Prescribers Scheme
Negative
- Significant equity dilution through 1.9 million stock options granted to IR firm
- Monthly IR expenses of up to US$13,500 represent additional operational costs
News Market Reaction – OPTHF
On the day this news was published, OPTHF gained 8.61%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psilocybin, is pleased to announce it has entered into an agreement with MZ Investor Relations ("MZ"), an investor relations firm. MZ will provide Optimi with strategic support in capital markets advisory, corporate communications, and investor engagement.
Under the terms of the engagement, MZ will be paid US
For more information on MZ, please visit: www.mzgroup.us.
Manufacturing Update
Optimi is also pleased to report a production milestone with the completion of manufacturing and encapsulation of over 3,000 GMP doses of its 5mg natural psilocybin extract capsules. A portion of this batch will be used to treat patients with Treatment-Resistant Depression (TRD) in Australia under its Authorized Prescribers Scheme, and to supply upcoming Phase 2 clinical trials in both Canada and abroad.
Ordering From Optimi
Licensed U.S. distributors and pharmaceutical companies holding the appropriate permits and DEA registrations may order Optimi's GMP-certified 40mg and 60mg MDMA capsules, 5mg natural psilocybin extract capsules, and API of both substances directly.
Authorized organizations in other jurisdictions with the required approvals and regulatory clearances may also access Optimi products for use in clinical trials, research, or compliant commercial distribution frameworks.
In Australia, entities seeking access to Optimi's MDMA and psilocybin products under the Authorized Prescribers Scheme may do so through Mind Medicine Australia.
To initiate procurement, contact:
sales@optimihealth.ca
About Optimi Health Corp.
Optimi Health Corp. is a Health Canada-licensed, GMP-compliant manufacturer and supplier of natural psilocybin and MDMA. Dedicated to producing high-quality psychedelic products, the Company aims to support the global advancement of mental health therapies through rigorous compliance, innovation, and collaboration.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10615/263172_42190ce5a465ba66_001full.jpg
On Behalf of the Board
JJ Wilson, Chair of the Board
For more information, please contact:
Optimi Health Corp.
Telephone: (778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"). Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's long form prospectus dated February 12, 2021, a copy of which is available on SEDAR+ at www.sedarplus.com. Except as expressly required by applicable law, Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263172
FAQ
What is the new manufacturing milestone announced by Optimi Health (OPTHF)?
What are the terms of Optimi Health's agreement with MZ Investor Relations?
What products does Optimi Health (OPTHF) currently manufacture?
How can organizations access Optimi Health's psilocybin and MDMA products?
